logo
Plus   Neg
Share
Email

Novartis: Cosentyx Shows Long-lasting Efficacy In FUTURE 5 Trial - Quick Facts

Novartis (NVS) said new data from the FUTURE 5 trial demonstrated that 89.5% (300mg), 82.3% (150mg) and 81.1% (150mg no loading dose) of psoriatic arthritis patients treated with Cosentyx found no radiographic progression at 2 years. Clinical responses were also maintained throughout the duration of the study.

FUTURE 5 is a Phase III, randomized, double-blind, placebo-controlled study evaluating Cosentyx on radiographic progression across 2 years in PsA patients. In the study, 996 adults with active PsA were randomized to receive subcutaneous Cosentyx 300 mg.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Whole Foods Market stores have recalled Decorated Red Apple Cookies as they may contain undeclared egg. People who have an allergy or severe sensitivity to these allergens run the risk of serious or life-threatening allergic reaction if they consume these products. The cookies were sold by the... Norwex has announced voluntary recall of about 58,000 rubber brooms due to laceration hazard. According to the company, handles of the recalled brooms can break in half, exposing a metal inner rim, posing a laceration hazard to the user. The recall involves extendable indoor/outdoor white rubber... Amazon.com Inc. has expanded its AmazonFresh grocery delivery service to three new cities. Beginning today, Amazon Prime members in Houston, Minneapolis and Phoenix can shop thousands of products, ranging from meat and seafood to fresh produce and everyday essentials. The groceries will be delivered to their homes in two hours or less, with options for one-hour and two-hour delivery.
Follow RTT